PRMT inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
E1349 TNG908 (Ralometostat) Ralometostat (TNG908) is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model.
S8664 GSK3326595 (Pemrametostat, EPZ015938) Pemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumour growth in vitro and in vivo in animal models.
MedComm (2020), 2025, 6(6):e70150
J Med Chem, 2025, 68(4):4217-4236
J Med Chem, 2025, 68(5):5097-5119
S8883 LLY-283 LLY-283 is a novel and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). This compound inhibits PRMT5 enzymatic activity in vitro and in cells with IC50 of 22 nM and 25 nM, respectively. It shows antitumor activity.
Mol Cancer Res, 2025, 23(2):107-118
Res Sq, 2025, rs.3.rs-5936706
Nat Commun, 2023, 14(1):1078
S6737 C7280948 C7280948 is a protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 12.8 μM in vitro.
Cell Death Differ, 2025, 10.1038/s41418-025-01585-6
Cell Death Dis, 2023, 14(4):233
Cell Death Dis, 2023, 14(8):512
S8858 GSK3368715 3HCl GSK3368715 3HCl is a potent inhibitor of type I protein arginine methyltransferases (PRMT) that inhibits PRMT1, 3, 4, 6 and 8 with Kiapp values ranging from 1.5 to 81 nM.
Nat Commun, 2023, 14(1):2806
Mol Cell, 2023, 83(15):2810-2828.e6
JCI Insight, 2022, 7(10)e151353
S0855 TC-E 5003 TC-E 5003 (NSC 30176, Compound 2e) is a selective inhibitor of protein arginine methyltransferase 1 (PRMT1) with IC50 of 1.5 μM. This compound modulates the lipopolysaccharide (LPS)-induced AP-1 and NF-κB signalling pathways and can possibly be further developed as an anti-inflammatory compound.
Biol Direct, 2025, 20(1):60
Hepatol Commun, 2025, 9(4)e0647
Mol Ther, 2023, 10.1016/j.ymthe.2023.09.011
E1024 MRTX1719 (Navlimetostat) MRTX1719 is a potent, selective inhibitor of the protein arginine methyltransferase 5·methylthioadenosine phosphorylase complex (PRMT5•MTA), a potentially tumour-selective target for therapeutic intervention.
bioRxiv, 2025, 2025.07.11.664387
Anticancer Res, 2024, 44(12):5231-5240
E1088 TP-064

TP-064 is a potent and selective small molecule inhibitor of PRMT4 with IC50 < 10 nM, >100 fold more selective for PRMT4 than other PRMTs.

Cell Rep Med, 2023, 4(12):101326
E1007 BRD0639

BRD0639 is a first-in-class PBM-competitive small molecule inhibitor that disrupts the PRMT5-RIOK1 complex with IC50s of 7.5 μM and 16 μM in permeabilised and living cells, respectively.

E7603 Furamidine dihydrochloride Furamidine dihydrochloride (DB75 dihydrochloride, NSC 305831 dihydrochloride) is a potent and selective inhibitor of protein arginine methyltransferase 1 (PRMT1) with an IC50 of 9.4 μM. It is also a potent inhibitor of tyrosyl-DNA phosphodiesterase (Tdp1). It exhibits potent anti-Plasmodium vivax and antiparasitic activity in vitro and in vivo, and its ability to disrupt mitochondrial membranes also supports its use as an antimicrobial agent.